Press release
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Approximately $35 million and $49 million unaudited global net product revenue of EKTERLY (sebetralstat) for the fourth quarter and full year 2025,
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\nApproximately $35 million and $49 million unaudited global net product revenue of EKTERLY (sebetralstat) for the fourth quarter and full year 2025, respectively\n\n\n1,318 patient start forms received in the US through December, reflecting continued rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE); Germany launch also demonstrating strong early adoption\n\n\nPartnered with Multicare Pharma to commercialize sebetralstat in Latin America; third commercial partnership in 10 months\n\n\n FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided its preliminary fourth quarter and full year ended December 31, 2025 unaudited global net product revenue results and other operational indicators.\n\n\n“We are extremely pleased with our performance since launching EKTERLY in July, which reflects steady execution, growing utilization, and continued momentum across our business,” said Ben Palleiko, CEO of KalVista. “Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to EKTERLY. Internationally, we are seeing strong uptake in Germany, with early prescribing behaviors mirroring the positive trends we observed in the US, and we expect to expand into other major markets during 2026. With EKTERLY rapidly emerging as the preferred on-demand HAE treatment, we remain committed to making it accessible to all people living with HAE, including pediatric patients aged 2-11 years, where we expect to file a new drug application in the third quarter.”\n\n\nEKTERLY® (sebetralstat) Commercial Progress\n\n\n\nInitiated the US commercial launch of EKTERLY on July 7, 2025, with approximately $35 million and $49 million unaudited global net product revenue for the fourth quarter and full year 2025, respectively.\n\n\n\nRecorded 1,318 patient start forms and activated 580 unique prescribers in the US through December 31, 2025.\n\n\n\nIn the fourth quarter of 2025, prescription refills surpassed initial prescriptions as the primary driver of revenue, with some activity potentially reflecting demand pulled forward ahead of the holidays.\n\n\n\nKalVista granted Multicare Pharmaceuticals, LLC exclusive rights to commercialize sebetralstat in Latin America. ...